AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

506.934

+7.7681.56%

Number of Gainers:17

Number of Losers:10

Number of Flat:16

PE:- -

High:510.015

Open:499.679

Low:495.260

Close:499.166

Volume:43.14M

Turnover:110.20M

Market Cap:70.37B

Float Cap:67.51B

Loading ...

Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

Simply Wall St.

We're Not Very Worried About Orthocell's (ASX:OCC) Cash Burn Rate

Simply Wall St.

Commonwealth Bank Stock And Other Dividend Compounders For Reliable Income

Simply Wall St.

Mesoblast Requests Modular Review of BLA for Rexlemestrocel-l in End-stage Heart Failure with LVAD

Australia's Immuron Rises as Company Seeks Partnership for New Drug

Carlisle Companies (CSL) Is Down 5.6% After Exit From Key Russell Defensive Indices Is The Bull Case Changed?

Simply Wall St.

Cynata Therapeutics Makes All Employee Positions Redundant Including CEO and MD

Immuron - Seeks Partners to Advance Clinical Development of Imm-529

THOMSON REUTERS

Cynata Therapeutics Ltd-final Director's Interest Notice

THOMSON REUTERS

Cynata Therapeutics - Makes All Employee Positions Redundant Including CEO and Md Effective 6 July 2026

THOMSON REUTERS

Cynata Therapeutics Ltd-board, Management Changes, Expenditure Reductions, Rdti Loan

THOMSON REUTERS

3 Founder Led ASX Stocks Retail Investors Are Watching For Management Alignment

Simply Wall St.

3 ASX Growth Companies With Up To 34% Insider Ownership

Simply Wall St.

Does CSL (ASX:CSL) Losing TAVNEOS Authorisation Undermine Its Diversification And Regulatory Resilience Story?

Simply Wall St.

Why Mesoblast (ASX:MSB) Is Up 9.3% After FDA Accepts Modular BLA Review For Rexlemestrocel-L

Simply Wall St.

Canaccord Genuity Downgrades Mayne Pharma Group to Speculative Buy From Buy; Price Target is AU$3.84

MT Newswires Live

Commonwealth Bank Stock And 2 Australian Dividend Shares For Reliable Income

Simply Wall St.

Australian Healthcare Stocks at Two-month High, CSL Rises over 3%

Cann Group - Additional A$2 Mln to Fund Approved Purposes Including Early Redemption of Convertible Notes

THOMSON REUTERS

Cann Group - Increases Private Credit Loan Facility by A$2 Mln

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK7508/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":506.9343,"timestamp":1783576799797,"preClose":499.16583,"halted":0,"volume":43140628,"delay":0,"changeRate":0.015563,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":7.768463,"latestTime":"07-09 16:00:00 AEST","open":499.6792,"high":510.01495,"low":495.25974,"amount":110196435,"amplitude":0.02956,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1783641600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1783555200000,1783576800000]],"turnoverRate":0.001692,"increases":16,"decrements":9,"flats":18,"marketCap":70373361301.5,"floatMarketCap":67513849864},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":510.01495,"amplitude":0.02956,"preClose":499.16583,"low":495.25974,"latestPrice":506.9343,"volume":43140628,"delay":0,"open":499.6792,"prevYearClose":644.3692,"prevWeekClose":490.461,"prevMonthClose":464.145,"prevQuarterClose":464.145,"fiveDayClose":476.564,"twentyDayClose":442.826,"sixtyDayClose":562.267,"secType":"PLATE","market":"AU","turnoverRate":0.001692,"marketCap":70373361301.5,"floatMarketCap":67513849864,"timestamp":1783576799797,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":17,"down":10,"flat":16},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2649667019","title":"Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2649667019","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649667019?lang=en_us&edition=fundamental","pubTime":"2026-07-07 05:53","pubTimestamp":1783374809,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ptx/prescient-therapeutics-shares/news/heres-why-were-not-too-worried-about-prescient-therapeutics-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ptx/prescient-therapeutics-shares/news/heres-why-were-not-too-worried-about-prescient-therapeutics-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK7508","PTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649679443","title":"We're Not Very Worried About Orthocell's (ASX:OCC) Cash Burn Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2649679443","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649679443?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:08","pubTimestamp":1783368480,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-occ/orthocell-shares/news/were-not-very-worried-about-orthocells-asxocc-cash-burn-rate-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-occ/orthocell-shares/news/were-not-very-worried-about-orthocells-asxocc-cash-burn-rate-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["OCC","OCC.AU","BK4020","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649679412","title":"Commonwealth Bank Stock And Other Dividend Compounders For Reliable Income","url":"https://stock-news.laohu8.com/highlight/detail?id=2649679412","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649679412?lang=en_us&edition=fundamental","pubTime":"2026-07-07 03:37","pubTimestamp":1783366654,"startTime":"0","endTime":"0","summary":"Dividend Powerhouses with yields above 5% can be especially appealing when inflation signals are mixed, growth is cooling in places, and central banks are rethinking rate paths. While bond yields and policy guidance move around, a well covered, growing and stable dividend stream offers a clearer source of potential cash flow. This Dividend Powerhouses screener focuses on exactly that: companies that combine higher income with balance sheet discipline. In this article, you will see 3 of the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/commonwealth-bank-stock-and-other-dividend-compounders-for-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/commonwealth-bank-stock-and-other-dividend-compounders-for-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VAP.AU","BK4585","ZYAU.AU","BK7104","BEAR.AU","GLTR","SLF.AU","QFN.AU","XAO.AU","IMLC.AU","XME","IOZ.AU","E200.AU","BK4588","DACE.AU","VAS.AU","BK7506","BK7508","GOAU","BK7135","GIVE.AU","OZF.AU","BBOZ.AU","SPHQ","BK7067","IIGF.AU","QRE.AU","GEAR.AU","PICK","XJO.AU","EIGA.AU","CBA.AU","UYM","IISV.AU","BK7501","STW.AU","EVN.AU","VIG","BK4535","CEF","BK7511","OZR.AU","XKO.AU","CSL.AU","GBUG","BEGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649864106","title":"Mesoblast Requests Modular Review of BLA for Rexlemestrocel-l in End-stage Heart Failure with LVAD","url":"https://stock-news.laohu8.com/highlight/detail?id=2649864106","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649864106?lang=en_us&edition=fundamental","pubTime":"2026-07-06 15:45","pubTimestamp":1783323913,"startTime":"0","endTime":"0","summary":"July 1 (Reuters) - Mesoblast Ltd::*REQUESTS MODULAR REVIEW OF BLA FOR REXLEMESTROCEL-L IN END-STAGE HEART FAILURE WITH LVAD*REXLEMESTROCEL-L RECEIVES ORPHAN DRUG AND RMAT DESIGNATIONS*Further company ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nRSD6tn3Cb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","BK7508","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649610841","title":"Australia's Immuron Rises as Company Seeks Partnership for New Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2649610841","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649610841?lang=en_us&edition=fundamental","pubTime":"2026-07-06 10:45","pubTimestamp":1783305926,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Immuron rises as company seeks partnership for new drug** Shares of Australia's ImmuronIMC.AXrise 11.1% to A$0.040, hitting their highest level since June 4** Stock marks its biggest intraday pct gain since June 1** The biopharmaceutical company says it is employing an advisory firm to help seek a partner to support clinical and commercial development of IMM-529** The IMM-529 is a product that can treat/prevent Clostridioides difficile infection, a contagious bacterial infection of the large intestine** Immuron stock up 11.1%, YTD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nL4N438046:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649136643","title":"Carlisle Companies (CSL) Is Down 5.6% After Exit From Key Russell Defensive Indices Is The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2649136643","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649136643?lang=en_us&edition=fundamental","pubTime":"2026-07-06 10:18","pubTimestamp":1783304334,"startTime":"0","endTime":"0","summary":"On 27 June 2026, Carlisle Companies Incorporated (NYSE: CSL) was removed from the Russell 1000 Defensive, Russell 1000 Value-Defensive, and Russell 1000 Growth-Defensive indices, prompting rebalancing by index-tracking funds.\nThis simultaneous exit from multiple Russell 1000 defensive-style indices matters because it can alter Carlisle’s investor base and share-trading patterns, with implications for liquidity and ownership mix.\nWe’ll now examine how Carlisle’s removal from several Russell...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3061000-choice1-main-header/1585186603448","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3061000-choice1-main-header/1585186603448"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/carlisle-companies-csl-is-down-56-after-exit-from-key-russel","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/carlisle-companies-csl-is-down-56-after-exit-from-key-russel","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1169590202.USD","BK7501","SG9999004303.SGD","BK4588","BK7508","OMFL","SGLC","BK7067","LU1169589451.USD","DEUS","SGXZ23171101.USD","BK4086","BK4581","CSL.AU","LU0728928796.USD","BK4585","CSL","BK7511","IWF","FLQL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649827617","title":"Cynata Therapeutics Makes All Employee Positions Redundant Including CEO and MD","url":"https://stock-news.laohu8.com/highlight/detail?id=2649827617","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649827617?lang=en_us&edition=fundamental","pubTime":"2026-07-06 09:47","pubTimestamp":1783302460,"startTime":"0","endTime":"0","summary":"BRIEF-Cynata Therapeutics Makes All Employee Positions Redundant Including CEO And MDJuly 6 -Cynata Therapeutics LtdCYP.AX:BOARD, MANAGEMENT CHANGES, EXPENDITURE REDUCTIONS, RDTI LOANMAKES ALL EMPLOYEE POSITIONS REDUNDANT INCLUDING CEO AND MD EFFECTIVE 6 JULY 2026Further company coverage:CYP.AX","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nTUE785S0X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYP.AU","BK7501","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649661126","title":"Immuron - Seeks Partners to Advance Clinical Development of Imm-529","url":"https://stock-news.laohu8.com/highlight/detail?id=2649661126","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649661126?lang=en_us&edition=fundamental","pubTime":"2026-07-06 07:19","pubTimestamp":1783293564,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260705:nFWN4350F3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMC.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649691611","title":"Cynata Therapeutics Ltd-final Director's Interest Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2649691611","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649691611?lang=en_us&edition=fundamental","pubTime":"2026-07-06 06:37","pubTimestamp":1783291072,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260705:nTUE7PX0ZL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CYP.AU","BK7067","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649664611","title":"Cynata Therapeutics - Makes All Employee Positions Redundant Including CEO and Md Effective 6 July 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2649664611","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649664611?lang=en_us&edition=fundamental","pubTime":"2026-07-06 06:35","pubTimestamp":1783290907,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260705:nTUE785S0X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CYP.AU","BK7067","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649261166","title":"Cynata Therapeutics Ltd-board, Management Changes, Expenditure Reductions, Rdti Loan","url":"https://stock-news.laohu8.com/highlight/detail?id=2649261166","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649261166?lang=en_us&edition=fundamental","pubTime":"2026-07-06 06:35","pubTimestamp":1783290907,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260705:nTUE785S0X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","BK7501","CYP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649146316","title":"3 Founder Led ASX Stocks Retail Investors Are Watching For Management Alignment","url":"https://stock-news.laohu8.com/highlight/detail?id=2649146316","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649146316?lang=en_us&edition=fundamental","pubTime":"2026-07-06 06:25","pubTimestamp":1783290328,"startTime":"0","endTime":"0","summary":"With central banks turning slightly less aggressive, inflation pressures mixed across regions and services sectors holding up better than expected in many countries, investors are again paying closer attention to stock selection rather than just macro headlines. Founder-led companies can be especially interesting in this context, as leaders with significant personal stakes often focus on building long term legacies instead of chasing short term targets. This Founder-Led Companies screener is...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/4484222-main-header/1585186590706","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/4484222-main-header/1585186590706"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/consumer-services/asx-flt/flight-centre-travel-group-shares/news/3-founder-led-asx-stocks-retail-investors-are-watching-for-m","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/consumer-services/asx-flt/flight-centre-travel-group-shares/news/3-founder-led-asx-stocks-retail-investors-are-watching-for-m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MQG.AU","BK7070","BK7042","BK7501","MSB.AU","BK7067","ISBC","MAQ.AU","BK7046","BK4211","BK7508","BK7511","FLT.AU","AIPO","BK7043"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649619107","title":"3 ASX Growth Companies With Up To 34% Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2649619107","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649619107?lang=en_us&edition=fundamental","pubTime":"2026-07-06 03:08","pubTimestamp":1783278496,"startTime":"0","endTime":"0","summary":"As the Australian market opens the new financial year on a flat note, global influences such as geopolitical tensions and tech sector enthusiasm continue to shape investor sentiment. In this landscape, growth companies with high insider ownership can be particularly appealing, as they often signal strong internal confidence and alignment with shareholder interests.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/3-asx-growth-companies-with-up-to-34-insider-ownership","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/3-asx-growth-companies-with-up-to-34-insider-ownership","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SPL.AU","MAF.AU","BK7508","XKO.AU","BK7017","XAO.AU","BK7084","BK7104","EIGA.AU","VAS.AU","XJO.AU","BK7501","SKS.AU","GIVE.AU","FRS.AU","BK7016","PNI.AU","BK7110","OZF.AU","AV1.AU","ZYAU.AU","AR1.AU","GYG.AU","SLF.AU","BK7095","IOZ.AU","IMLC.AU","AEM.AU","TOR.AU","E200.AU","STW.AU","BBOZ.AU","GEAR.AU","ELS.AU","IIGF.AU","QRE.AU","TLX.AU","BEAR.AU","BK7067","BK7137","BK4139","QFN.AU","DACE.AU","VAP.AU","IISV.AU","OZR.AU","EMR.AU","TLX","BK7096","BK7023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649691995","title":"Does CSL (ASX:CSL) Losing TAVNEOS Authorisation Undermine Its Diversification And Regulatory Resilience Story?","url":"https://stock-news.laohu8.com/highlight/detail?id=2649691995","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649691995?lang=en_us&edition=fundamental","pubTime":"2026-07-04 22:25","pubTimestamp":1783175140,"startTime":"0","endTime":"0","summary":"The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended revoking CSL Vifor’s TAVNEOS marketing authorisation in the EU, after finding manipulated and unreliable pivotal trial data and prompting CSL to halt new patient starts across EMA jurisdictions.\nThis setback not only raises the prospect of an impairment charge for TAVNEOS intellectual property, but also highlights how regulatory scrutiny can directly test CSL’s diversification benefits and risk...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/does-csl-asxcsl-losing-tavneos-authorisation-undermine-its-d","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/does-csl-asxcsl-losing-tavneos-authorisation-undermine-its-d","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","AIPO","BK7508","BK4086","LU1169589451.USD","BK7501","CSL","LU0728928796.USD","SG9999004303.SGD","LU1169590202.USD","BK7511","SGXZ23171101.USD","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648015660","title":"Why Mesoblast (ASX:MSB) Is Up 9.3% After FDA Accepts Modular BLA Review For Rexlemestrocel-L","url":"https://stock-news.laohu8.com/highlight/detail?id=2648015660","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648015660?lang=en_us&edition=fundamental","pubTime":"2026-07-04 00:35","pubTimestamp":1783096506,"startTime":"0","endTime":"0","summary":"In late June 2026, Mesoblast received a Biologics License Application filing number from the U.S. FDA and requested modular review for rexlemestrocel-L to prevent life-threatening gastrointestinal bleeding in end-stage heart failure patients supported by left ventricular assist devices, building on its Orphan Drug and RMAT designations.\nThe filing comes as new FDA draft guidance reiterates a flexible approach to therapies for rare, high-mortality conditions, potentially aligning closely with...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/why-mesoblast-asxmsb-is-up-93-after-fda-accepts-modular-bla","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/why-mesoblast-asxmsb-is-up-93-after-fda-accepts-modular-bla","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK4006","LABU","BK4588","BK4585","BK7508","BK7501","MSB","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648663573","title":"Canaccord Genuity Downgrades Mayne Pharma Group to Speculative Buy From Buy; Price Target is AU$3.84","url":"https://stock-news.laohu8.com/highlight/detail?id=2648663573","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648663573?lang=en_us&edition=fundamental","pubTime":"2026-07-03 18:55","pubTimestamp":1783076134,"startTime":"0","endTime":"0","summary":"Canaccord Genuity Downgrades Mayne Pharma Group to Speculative Buy From Buy; Price Target is AU$3.84","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","MYX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648165489","title":"Commonwealth Bank Stock And 2 Australian Dividend Shares For Reliable Income","url":"https://stock-news.laohu8.com/highlight/detail?id=2648165489","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648165489?lang=en_us&edition=fundamental","pubTime":"2026-07-03 14:36","pubTimestamp":1783060582,"startTime":"0","endTime":"0","summary":"In a world where inflation signals, interest rate expectations and growth data keep shifting, many investors are looking for income that feels more reliable than the latest macro headline. That is where Dividend Powerhouses with yields above 5% and well covered, growing payouts can help. This screener focuses on companies that have kept dividends both stable and on an upward path, which can be appealing when bond yields, labor data and central bank messages keep moving around. In this...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/commonwealth-bank-stock-and-2-australian-dividend-shares-for-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/commonwealth-bank-stock-and-2-australian-dividend-shares-for-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7506","BK7511","GIVE.AU","VAP.AU","QRE.AU","US7Y.BOND","XKO.AU","BK7135","EIGA.AU","BK7067","IOZ.AU","US2Y.BOND","E200.AU","BEAR.AU","CBA.AU","OZF.AU","STW.AU","BBOZ.AU","TMF","XJO.AU","IMLC.AU","US30Y.BOND","QFN.AU","IISV.AU","US10Y.BOND","ARTY","TLT","US6M.BOND","GEAR.AU","US3Y.BOND","US5Y.BOND","AGIX","XAO.AU","OZR.AU","VAS.AU","DACE.AU","TLTW","IIGF.AU","BK7501","US12M.BOND","BK7508","CHAT","CSL.AU","AIPO","ZYAU.AU","NST.AU","BK7104","SLF.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648665536","title":"Australian Healthcare Stocks at Two-month High, CSL Rises over 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648665536","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648665536?lang=en_us&edition=fundamental","pubTime":"2026-07-03 13:48","pubTimestamp":1783057739,"startTime":"0","endTime":"0","summary":"BUZZ-Australian healthcare stocks at two-month high, CSL rises over 3%** Australian health stocks.AXHJrise as much as 2.7%, their highest level since April 22** Stocks gain more than 5% so far this week, their best level since early-November, 2022** Extends gains for a seventh consecutive week** \"Healthcare was battered in the last FY, and has been stabilising in the last couple of months, and investors are finally waking up to how cheap they are in a historical context,\" says Mark Gardner, founder and chief executive officer at MPC Markets** Shares of CSLCSL.AXand CochlearCOH.AXgain over 3% each** Sub-index down ~20% YTD, including the session's moves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260703:nL6N4350AF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COH.AU","CSL.AU","BK7501","BK7508","BK7007","BK7511","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648653307","title":"Cann Group - Additional A$2 Mln to Fund Approved Purposes Including Early Redemption of Convertible Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2648653307","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648653307?lang=en_us&edition=fundamental","pubTime":"2026-07-03 12:55","pubTimestamp":1783054547,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260703:nFWN4340YK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CAN.AU","BK7502","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648300653","title":"Cann Group - Increases Private Credit Loan Facility by A$2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2648300653","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648300653?lang=en_us&edition=fundamental","pubTime":"2026-07-03 12:55","pubTimestamp":1783054547,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260703:nFWN4340YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7502","CAN.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":112,"code":"91000000","status":"200"}]}}